Risk factors and prognosis of seizures in adults with community-acquired bacterial meningitis in Denmark:observational cohort studies by Larsen, Fredrikke Tove Birgitta Dam et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Risk factors and prognosis of seizures in adults with community-acquired bacterial
meningitis in Denmark
DASGIB study group
Published in:
BMJ Open
DOI:
10.1136/bmjopen-2019-030263
Publication date:
2019
Document version
Publisher's PDF, also known as Version of record
Citation for published version (APA):
DASGIB study group (2019). Risk factors and prognosis of seizures in adults with community-acquired bacterial
meningitis in Denmark: observational cohort studies. BMJ Open, 9, [e030263]. https://doi.org/10.1136/bmjopen-
2019-030263
Download date: 03. Feb. 2020
1Larsen FTBD, et al. BMJ Open 2019;9:e030263. doi:10.1136/bmjopen-2019-030263
Open access 
Risk factors and prognosis of seizures in 
adults with community-acquired 
bacterial meningitis in Denmark: 
observational cohort studies
Fredrikke Tove Birgitta Dam Larsen,1 Christian Thomas Brandt,2 Lykke larsen,3 
Vibeke Klastrup,4 Lothar Wiese,5 Jannik Helweg-Larsen,6 Birgitte Rønde Hansen,7 
Christian Østergaard Andersen,8 Henrik Nielsen,1 Jacob Bodilsen,1 On behalf of the 
DASGIB study group
To cite: Larsen FTBD, Brandt CT, 
larsen L, et al.  Risk factors 
and prognosis of seizures 
in adults with community-
acquired bacterial meningitis 
in Denmark: observational 
cohort studies. BMJ Open 
2019;9:e030263. doi:10.1136/
bmjopen-2019-030263
 ► Prepublication history for 
this paper is available online. 
To view these files please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2019- 
030263).
Received 7 March 2019
Revised 24 May 2019
Accepted 10 June 2019
For numbered affiliations see 
end of article.
Correspondence to
Dr Jacob Bodilsen;  
 Jacob. bodilsen@ rn. dk
Research
© Author(s) (or their 
employer(s)) 2019. Re-use 
permitted under CC BY-NC. No 
commercial re-use. See rights 
and permissions. Published by 
BMJ.
AbstrACt 
Objective To examine predefined risk factors and 
outcome of seizures in community-acquired bacterial 
meningitis (CABM).
Design Observational cohort studies
setting Denmark
Participants In the derivation cohort, we retrospectively 
included all adults (>15 years of age) with CABM in North 
Denmark Region from 1998 to 2014 and at Hvidovre and 
Hillerød hospitals from 2003 to 2014. In the validation 
cohort, we prospectively included all adults (>18 years of 
age) with CABM treated at all departments of infectious 
diseases in Denmark from 2015 to 2017.
Primary and secondary outcome measures In the 
derivation cohort, we used modified Poisson regression to 
compute adjusted relative risks (RRs) with 95% confidence 
intervals for predefined risk factors for seizures during 
CABM as well as for risks of death and unfavourable 
outcome assessed by the Glasgow Outcome Scale score 
(1-4). Next, results were validated in the validation cohort.
results In the derivation cohort (n=358), risk factors 
for seizures at any time were pneumococcal aetiology 
(RR 1.69, 1.01–2.83) and abnormal cranial imaging (RR 
2.27, 1.46–3.53), while the impact of age >65 years and 
immunocompromise was more uncertain. Examining 
seizures occurring after admission, risk factors were 
abnormal cranial imaging (RR 2.23, 1.40–3.54) and 
immunocompromise (RR 1.59, 1.01–2.50). Seizures at any 
time were associated with increased risks of in-hospital 
mortality (RR 1.45, 1.01–2.09) and unfavourable outcome 
at discharge (RR 1.27, 1.02–1.60). In the validation cohort 
(n=379), pneumococcal aetiology (RR 1.69, 1.10–2.59) 
and abnormal cranial imaging (RR 1.68, 1.09–2.59) were 
confirmed as risk factors for seizures at any time. For 
seizures occurring after admission, only pneumococcal 
meningitis (RR 1.92, 1.12–3.29) remained significant. 
Seizures at any time were also associated with in-hospital 
mortality (RR 3.26, 1.83–5.80) and unfavourable outcome 
(RR 1.23, 1.00–1.52) in this cohort.
Conclusions Pneumococcal aetiology, 
immunocompromise and abnormal cranial imaging were 
risk factors for seizures in CABM. Seizures were strongly 
associated with mortality and unfavourable outcome.
IntrODuCtIOn
Community-acquired bacterial meningitis 
(CABM) is a devastating and often fatal 
condition. Seizures are frequent in CABM 
and have been associated with increased case 
fatality.1–5 The pathogenesis of seizures in 
CABM may involve inflammatory neuronal 
excitation, necrosis and increased intracra-
nial pressure. A previous study compared 
patients with CABM complicated by seizures 
to those without seizures and found that they 
more often had cerebrospinal fluid (CSF) 
leucocytes <1000/mL, CSF protein >3.0 g/L, 
increased erythrocyte sedimentation rate, a 
pneumococcal aetiology and focal cerebral 
abnormalities.1 
Some authors advocate routine adminis-
tration of anticonvulsive therapy in patients 
with suspected pneumococcal meningitis 
strengths and limitations of this study
 ► Using a two-cohort design, we first analysed the 
data in a retrospective population-based derivation 
cohort and next validated the results in a contem-
porary prospective nationwide population-based 
observational cohort.
 ► We defined risk factors and specified adjustments 
prior to data acquisition and analyses based on pre-
vious studies and biological reasoning.
 ► We included clinically meaningful risk factors 
amenable for future improvement such as antibiotic 
delay and treatment with adjunctive dexamethasone.
 ► Risk factors were also examined in stratified anal-
yses of seizures occurring before or immediately at 
admission and seizures occurring during admission.
 ► Limitations inherent of retrospective designs also 
applied to our study including unavailability of elec-
troencephalographs, random missing values and 
non-standardised treatment.
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irrespective of whether or not seizures have occurred.2 
This recommendation, however, has not been formally 
shown to improve the prognosis and is not adopted by 
most guidelines.6 7 So far, few studies have specifically 
addressed risk factors and prognosis of seizures in CABM 
and previous results should be validated in other cohorts. 
A better understanding of clinical characteristics associ-
ated with increased risk of seizures could help define a 
population of adult patients eligible for a clinical trial of 
anticonvulsive therapy in CABM.
Therefore, we aimed to examine predefined risk 
factors for seizures in adult patients with CABM and the 
prognostic effect of seizures on outcome in a retrospec-
tive cohort. Next, we validated our results in a nationwide 
prospective bacterial meningitis cohort.
MAterIAl AnD MethODs
setting and study population
In Denmark, healthcare is financed by taxes and there-
fore free of charge at the point of delivery. All residents 
are assigned a unique 10-digit personal identification 
number at birth or immigration, which can be used to 
access information from all hospitalisations and other 
healthcare-related contacts.
Derivation cohort
We combined two retrospective cohorts of adult patients 
with CABM from North Region Denmark (1998–2014) 
and Nordsjællands and Hvidovre Hospitals (2003–2014) 
as described previously (figure 1).8 We used the elec-
tronic laboratory information systems to identify patients 
(ADBakt, Autonik Sweden at the Department of Clinical 
Microbiology at Aalborg University Hospital and LABKA 
II, CSC Scandihealth, Denmark, at the Departments of 
Clinical Biochemistry at Hvidovre and Nordsjællands 
Hospitals). We included all patients >15 years of age with 
a clinical presentation suggesting CABM and at least one 
of the following criteria8:
1. Positive CSF culture.
2. Positive blood culture and CSF pleocytosis >10 leuco-
cytes/mL.
3. Presence of bacteria on Gram stain of CSF.
4. Non-culture detection of bacteria in CSF by PCR-based 
technology or antigen analyses.
Figure 1 Flowchart of included patients with CABM in the derivation and validation cohorts. CABM, community-acquired 
bacterial meningitis; CNS, central nervous system.
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Exclusion criteria were previous neurosurgery, primary 
brain abscesses or hospital-acquired bacterial menin-
gitis as defined by the Centers for Disease Control and 
Prevention.9
Patient data
We used the medical records to examine baseline charac-
teristics including patient history, symptoms and signs at 
admission, time of diagnosis (at admission or later), adju-
vant dexamethasone treatment and laboratory results 
(biochemistry, radiology, microbiology). For radiological 
results, we relied on the radiologist’s descriptions. We 
defined immunocompromise as presence of any of the 
following comorbidities: alcohol abuse, asplenia, diabetes 
mellitus, renal impairment, liver cirrhosis, immunosup-
pressive therapy (eg, chemotherapy or high-dose pred-
nisolone), solid or haematological cancer. Observation 
charts were obtained for patients who were treated in 
an intensive care unit (ICU). For patients with seizures, 
we included prior history of seizure disorder, use of anti-
convulsive therapy as well as type, day(s) and cumulative 
incidence of seizures during admission for CABM. Elec-
troencephalographs (EEGs) were not available in the 
medical records. We used the Glasgow Outcome Scale 
(GOS) score at discharge for assessment of outcome and 
categorised a GOS score of 5 as favourable, while GOS 
1–4 were considered an unfavourable outcome.
Validation cohort
We used the Danish Study Group of Infections of the 
Brain (DASGIB) bacterial meningitis cohort to validate 
our results.10 Briefly, all adults with central nervous system 
infections treated by departments of infectious diseases in 
Denmark have been prospectively included in a database 
since 1 January 2015. The database contains information 
on baseline demographics, signs and symptoms at admis-
sion, time to antibiotic therapy for CABM, laboratory and 
imaging results, complications during admission and GOS 
scores at discharge. As in the derivation cohort, episodes 
of seizures analysed in this study were restricted to those 
occurring before or at some point during admission or 
stay at rehabilitation unit until discharge to home or 
nursing home. We validated our findings among patients 
with CABM registered in the DASGIB cohort from year 
2015 through 2017. Prior to carrying out the current 
study, the DASGIB cohort was first registered on www. clin-
icaltrials. gov (NCT03418441) on February 1, 2018.
statistical analyses
Baseline data are presented in contingency tables. 
Categorical variables are presented as proportions with 
percentages (%) and examined by Fisher’s exact test or 
Χ2, while continuous variables are presented as medians 
with IQR and compared by Mann-Whitney U-test.
Using modified Poisson regression analyses, we 
computed adjusted relative risks (RRs) with 95% CIs 
for seizures at any time and for new onset seizures after 
admission only.11 Based on previous studies and biological 
plausibility, our prespecified variables consisted of: 
Age >65 years, immunocompromise, pneumococcal aeti-
ology, time to antibiotic therapy for CABM within 2 hours 
of admission, adjunctive dexamethasone treatment 
and abnormal cranial imaging.1 Examining risk factors 
for new onset seizures after admission in the validation 
cohort, a limited number of events (n=44) restricted the 
analysis to four prioritised variables: Age >65 years, immu-
nocompromise, pneumococcal aetiology and abnormal 
cranial imaging.
Next, we used similar multivariable analyses to compute 
the prognostic value of seizures at any time during CABM 
on risk of death and unfavourable outcome at discharge. 
These analyses of outcome were adjusted for age >65 
years, sex, diagnosis of meningitis immediately at admis-
sion, time to antibiotic therapy for CABM within 2 hours of 
admission, pneumococcal aetiology, adjuvant dexametha-
sone treatment and GCS <15 at admission. However, time 
of diagnosis was not available in the DASGIB database 
and was therefore omitted from the adjusted outcome 
analyses in this cohort. We also performed a sensitivity 
analysis of risk factors and outcome excluding the five 
patients with known seizure disorder.
We used STATA MP V.15.1 for all statistical analyses.
ethics
The study was notified to the Danish Data Protection 
Agency in North Denmark Region (record no. 2008-58-
0028) and Capital Region of Denmark (record no. 01 706 
hvh-2012–016, NOH-2015–012) and the Danish Health 
and Medicines Authority (record no. 3-3013-135/1 and 
3-3013-2579/1). An approval from an ethics committee is 
not required for this type of study in Denmark.
Patient and public involvement
Neither patients nor public institutions were involved in 
this study. There are no plans of disseminating the results 
of this report to study participants besides publication in 
an open-access medical journal.
results
Derivation cohort
Seizures at any time during CABM occurred in 62 of 358 
(17%) patients in the derivation cohort of whom 23 (6%) 
had seizures before or immediately at the time of admis-
sion (table 1).
Five (9%) of these patients had a known seizure 
disorder before CABM. For 15 patients, the day and type 
of seizures in CABM were not specified in the medical 
records. The median time of first seizure episode in 
patients only having seizures during admission was day 1 
(IQR 1–2). Types of seizures observed were generalised in 
34 patients, focal in 10 of which 4 had secondary gener-
alisation and non-convulsive status epilepticus in 3. The 
median number of days with seizures was 1 (IQR 1–2, 
range 1–23). Treatment for seizures was administered to 
43 of 62 (69%) patients of whom 30 (48%) were given 
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combination anticonvulsive therapy (9 patients if combi-
nations with benzodiazepines were not included). Anti-
convulsive treatments used included benzodiazepines 
in 30 (48%) patients, sedation in the ICU in 17 (27%), 
valproate in 11 (18%), phenytoin in 5 (8%), lamotrigine 
in 2 (3%), levetiracetam in 2 (3%), oxcarbazepine and 
carbamazepine in 1 each (2%).
Comparing patients with seizures at any time during 
CABM to patients without seizures, we observed no 
substantial differences in most presenting symptoms or 
baseline blood and CSF biochemistry (table 1). However, 
focal neurological deficits (13 of 62 (21%) vs 31 of 296 
(11%)) and altered mental status (53 of 62 (85%) vs 
213 of 296 (72%)) were more common in these patients 
than in patients without seizures. Seizures occurred in 
43 of 194 (22%) patients with pneumococcal meningitis 
compared with 19 of 145 (13%) patients with other aeti-
ologies (table 2).
Conversely, seizures were only observed among 3 of 59 
(5%) patients with meningococcal meningitis. Abnor-
malities in cranial imaging were found in 28 of 57 (48%) 
patients with seizures compared with 62 of 209 (30%) 
Table 1 Baseline characteristics of patients with community-acquired bacterial meningitis with and without seizures at any 
time during admission
Baseline characteristics
Seizures
(n=62) No seizures (n=296) P value
Age (IQR), n=358 63 (51–70) 58.5 (46–70) 0.13
Female 27/62 (44) 152/296 (51) 0.26
Immunocompromise, n=358 28/62 (45) 95/296 (32) 0.049
  Diabetes mellitus 7/62 (11) 17/296 (6) 0.11
  Alcohol abuse 11/62 (18) 39/296 (13) 0.35
Otitis/sinusitis/mastoiditis/pneumonia 31/62 (50) 107/296 (36) 0.04
Duration of symptoms (days), n=183 2 (2–3.5) 2 (2–5) 0.42
Symptoms and signs on presentation
  Headache 36/49 (73) 175/234 (75) 0.85
  Nausea/Vomiting 21/45 (47) 93/201 (46) 0.96
  Neck stiffness 38/58 (66) 180/273 (66) 0.95
  Temperature (°C), n=327 38.8 (37.8–39.7) 39.0 (37.9–39.7) 0.73
  Petechiae 10/48 (21) 49/216 (23) 0.78
  Focal neurological deficits 13/62 (21) 31/294 (11) 0.02
Glasgow Coma Scale <15, n=358 53 (85) 213 (72) 0.03
Diagnosed before or at admission, n=358 37 (60) 208 (70) 0.10
Time to antibiotic therapy for meningitis since admission (hours), n=333 2.8 (1.0–12) 2.45 (1–8) 0.57
Laboratory results
  C-reactive protein (mg/L), n=358 204 (108–327) 215 (115–303) 0.74
  B-leucocytes (109/L), n=332 17 (10–25) 17 (12–23) 0.67
  B-thrombocytes (109/L), n=307 197 (130–268) 199 (131–272) 0.77
  S-creatinine (µmol/L), n=318 92 (66–138) 81 (64–107) 0.19
  CSF leucocytes (median, IQR) (106/L), n=346 2806 (287–6845) 2110 (483–5520) 0.82
  Protein in CSF (g/L), n=323 4.3 (2.1–9.1) 3.6 (1.8–6.5) 0.09
  CSF:blood glucose ratio (mmol/L), n=323 1.2 (0.1–2.8) 1.1 (0.1–3.0) 0.96
Positive blood culture, n=358 41 (66) 167 (56) 0.29
Positive CSF culture, n=358 51 (82) 247 (83) 0.34
Pneumococcal aetiology, n=358 43 (69) 151 (51) 0.008
Meningococcal aetiology, n=358 3 (5) 56 (19) 0.007
Adjunctive dexamethasone treatment, n=358 33 (53) 148 (50) 0.66
Intensive care unit treatment, n=358 57 (92) 149 (51) <0.001
Data presented as n/N (%) or medians (IQR).
Immunocompromise: alcohol abuse, asplenia, diabetes mellitus, renal impairment, liver cirrhosis, immunosuppressive therapy (eg, 
chemotherapy or high-dose prednisolone), solid or haematological cancer.
CSF,  cerebrospinal fluid.   
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patients without seizures with infarction as the most 
common finding (table 3).
Twenty-two of 62 (35%) patients with seizures died 
during admission for CABM versus 62 of 296 (21%) in 
patients without seizures, while unfavourable outcome 
at discharge occurred in 39 of 62 (63%) versus 127 of 
296 (43%) patients (table 4). There was no difference in 
fatal outcome among patients with seizures who received 
anti-epileptic treatment and those who did not (17 of 43 
(40%) versus 5 of 19 (26%) patients, p=0.32).
Examining risk factors for seizures at any time during 
admission by univariable and multivariable analyses, we 
observed an increased risk in patients with pneumococcal 
aetiology (adjusted RR 1.69, 95% CI 1.02 to 2.83) and 
abnormal cranial imaging (adjusted RR 2.27, 95% CI 1.46 
to 3.53) compared with patients without these character-
istics (tables 5 and 6).
Restricting the multivariable analysis to patients with 
seizures during admission, only abnormal cranial imaging 
(adj. RR 1.90, 95% CI 1.21 to 2.98) and immunocompro-
mise (adj. RR 1.62, 95% CI 1.01 to 2.57) were significantly 
associated with increased risk, while pneumococcal aeti-
ology also suggested an association (adj. RR 1.65, 95% CI 
0.99 to 2.76). Significant associations between seizures 
and abnormal cranial imaging were confirmed in strati-
fied analyses of pneumococcal aetiology (data not shown).
Seizures at any time during CABM increased the risk 
of case fatality by 45% (adj. RR 1.45, 95% CI 1.01 to 2.09) 
and the risk of unfavourable outcome at discharge by 
Table 2 Causative pathogens of community-acquired 
bacterial meningitis in patients with and without seizures at 
any time during admission
Bacterial aetiology
Seizures 
(n=62)
No seizures 
(n=296)
Streptococcus pneumoniae 43 (69) 151 (51)*
Neisseria meningitidis 3 (5) 56 (19)*
Listeria monocytogenes 4 (6) 22 (7)
Beta-haemolytic streptococci 
(A, B, C, G)
4 (6) 10 (3)
Non-haemolytic streptococci 2 (3) 6 (2)
Staphylococcus aureus 1 (2) 20 (7)
Escherichia coli - 8 (3)
Haemophilus influenzae 3 (5) 13 (4)
Capnocytophaga canimorsus - 5 (2)
Klebsiella pneumonia - 1 (1)
Enterococcus spp. 1 (2) 3 (1)
Pasteurella multocida 1 (2) -
Chlamydia pneumoniae - 1 (1)
Data are presented as n (%).
*P value <0.05.
Table 3 Cranial imaging in patients with community-acquired bacterial meningitis with or without seizures at any time during 
admission
Baseline characteristics
Seizures
(n=57) No seizures (n=209) P value
Abnormal cranial imaging 28 (49) 62 (30) 0.006
Infarction 15 (26) 23 (11) 0.003
Generalised brain swelling 7 (12) 15 (7) 0.22
Haemorrhage 4 (7) 14 (7) 0.93
Hydrocephalus 0 10 (5) 0.09
Ventriculitis 1 (2) 5 (2) 0.77
Cerebritis 1 (2) 4 (2) 0.94
Malignant tumour 1 (2) 2 (1) 0.61
Secondary brain abscess/empyema 2 (4) 1 (1) 0.06
Sinus thrombosis 1 (2) 1 (1) 0.32
Data are presented as n (%).
Table 4 Outcomes of patients with community-acquired 
bacterial meningitis with or without seizures at any time 
during admission
Outcome
Seizures 
(n=62)
No seizures 
(n=296)
Glasgow Outcome Scale score
  1 22 (35) 62 (21)*
  2 - 2 (1)
  3 7 (11) 28 (9)
  4 10 (16) 35 (12)
  5 23 (37) 169 (57)*
Seizures after discharge/subsequent 
epilepsy
7/62 (13) Na
Duration of admission (days), n=358 21 (12–36) 14 (10–23)*
Time to death (days), n=358 7 (3–27) 8 (3–16)
Data are presented as n (%) or medians (IQR).
*P value <0.05.
Na, not available.
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27% (adj. RR 1.27, 95% CI 1.02 to 1.60). Stratified anal-
yses of pneumococcal meningitis patients with seizures at 
any time during admission compared with those without 
seizures showed an increased case fatality (14 of 43 (33%) 
vs 31 of 151 (21%), p=0.10) and risk of unfavourable 
outcome at discharge (28 of 43 (65%) vs 70 of 151 (46%), 
p=0.03).
Validation cohort
Next, we validated our results among 379 adult patients 
(47% female) with CABM in the DASGIB cohort. The 
median age was 66 years (IQR 54–74) and seizures at 
any time during admission occurred in 69 of 379 (18%) 
patients. The aetiology was predominated by Streptococcus 
pneumoniae (41%) followed by Staphylococcus aureus (10%) 
and beta-haemolytic streptococci (5%). A fatal outcome 
was observed in 50 of 379 (13%) patients, while an unfa-
vourable outcome at discharge was found in 199 of 379 
patients (53%) in this cohort.
We confirmed that pneumococcal aetiology (adj. RR 
1.69, 95% CI 1.10 to 2.59) and abnormal cranial imaging 
(adj. RR 1.68, 95% CI 1.09 to 2.59) were associated with 
increased risks of seizures at any time during admission 
(table 6). When we restricted the analysis to seizures after 
admission, only pneumococcal aetiology remained asso-
ciated with increased risks (adj. RR 1.92, 95% CI 1.12 to 
3.29). Seizures at any time during CABM increased the 
risk for case fatality by 226% (adj. RR 3.26, 95% CI 1.83 to 
5.80) and for unfavourable outcome at discharge by 23% 
(adj. RR 1.23, 95% CI 1.00 to 1.52).
Table 5 Univariate analysis for risk factors of seizures in CABM using patients with no seizures as reference
Risk factor for seizures during CABM Retrospective cohort (n=358) Prospective cohort (n=379)
Seizures at any time during infection n=62 (17%) n=69 (18%)
Age >65 years 1.46 (0.93 to 2.29) 1.54 (0.99 to 2.41)
Immunocompromise 1.57 (1.00 to 2.47) 1.56 (1.02 to 2.40)
  Diabetes mellitus 1.77 (0.91 to 3.46) 2.21 (1.35 to 3.64)
  Alcohol abuse 1.33 (0.74 to 2.37) 1.27 (0.64 to 2.53)
Abnormal cranial imaging 2.45 (1.58 to 3.81) 1.76 (1.15 to 2.69)
Pneumococcal aetiology 1.91 (1.16 to 3.15) 1.58 (1.03 to 2.41)
Diagnosed immediately at admission 0.68 (0.43 to 1.08) -
Antibiotics for meningitis within 2 hours 0.98 (0.62 to 1.55) 0.84 (0.53 to 1.33)
Adjunctive dexamethasone treatment 1.11 (0.71 to 1.75) 0.83 (0.53 to 1.28)
Glasgow Coma Scale at admission <15 2.04 (1.05 to 3.97) 2.12 (1.29 to 3.48)
C-reactive protein >100 mg/L 0.86 (0.50 to 1.48) 0.71 (0.45 to 1.12)
CSF leucocytes <1000/mL 0.94 (0.58 to 1.52) 0.98 (0.64 to 1.51)
CSF protein >3.0 g/L 1.29 (0.29 to 2.10) 1.81 (1.17 to 2.82)
Seizures during admission n=58 (16%) n=46 (12%)
Age >65 years 1.53 (0.96 to 2.45) 1.64 (0.93 to 2.91)
Seizures before or immediately at admission 6.44 (4.41 to 9.40) 5.01 (1.84 to 13.7)
Immunocompromise 1.78 (1.12 to 2.85) 1.39 (0.80 to 2.41)
  Diabetes mellitus 1.91 (0.97 to 3.75) 2.32 (1.22 to 4.41)
  Alcohol abuse 1.44 (0.80 to 2.59) 1.07 (0.41 to 2.79)
Abnormal cranial imaging 2.42 (1.53 to 3.83) 1.66 (0.96 to 2.87)
Pneumococcal aetiology 1.88 (1.12 to 3.15) 1.88 (1.09 to 3.24)
Diagnosed immediately at admission 0.61 (0.38 to 0.97) -
Antibiotics for meningitis within 2 hours 0.96 (0.59 to 1.55) 0.78 (0.43 to 1.41)
Adjunctive dexamethasone treatment 1.29 (0.80 to 2.08) 0.67 (0.39 to 1.15)
Glasgow Coma Scale at admission <15 1.48 (0.80 to 2.73) 1.71 (0.94 to 3.09)
C-reactive protein >100 mg/L 1.37 (0.71 to 2.66) 0.71 (0.40 to 1.27)
CSF leucocytes <1000/mL 1.21 (0.75 to 1.96) 1.14 (0.66 to 1.96)
CSF protein >3.0 g/L 1.48 (0.87 to 2.50) 2.19 (1.23 to 3.88)
Data are presented as relative risks with 95% CI.
CABM, community-acquired bacterial meningitis; CSF, cerebrospinal fluid.
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Supplementary analyses in both the derivation and 
validation cohorts revealed no substantial effects of time 
to antibiotic therapy for CABM within 2 hours of admis-
sion or adjunctive dexamethasone on risks of seizures in 
CABM (tables 5 and 6).
Sensitivity analyses excluding patients with known 
seizure disorder (n=5) did not change the overall results 
of risk factors or prognosis in either cohort.
DIsCussIOn
We examined the association between several predefined 
variables and risk of seizures in adult CABM in two 
separate observational cohorts and identified pneumo-
coccal meningitis, immunocompromise and abnormal 
cranial imaging (cerebral infarctions) as important risk 
factors. In addition, seizures were strongly associated with 
mortality and unfavourable outcome at discharge.
Comparisons with other studies
Few previous studies have specifically addressed risk 
factors for seizures in bacterial meningitis.1–5 A prospec-
tive Dutch observational study examined 696 episodes 
of CABM from 1998 through 2002 and found that 121 
(17%) of patients had seizures at some point during infec-
tion,1 which is identical to the findings in our study. They 
also observed several differences between patients with 
and without seizures by univariate analyses, for example, 
in CSF biochemistry. However, in multivariable analyses, 
only immunocompromise and pneumococcal meningitis 
remained strongly associated with seizures at any time 
with the addition of focal cerebral abnormalities (defined 
as aphasia, monoparesis, hemiparesis or quadriparesis) 
for seizures after 48 hours of admission. The focal cere-
bral abnormalities may be correlates of brain infarctions 
as suggested by the high prevalence among patients with 
seizures compared with patients without seizures (20% vs 
11%). Therefore, we consider the overall results compa-
rable to ours with small differences in the methodology.
In our study, brain infarctions were found in 26% of 
CABM patients with seizures and 11% of those without 
seizures. In comparison, the incidence of seizures within 
2 weeks among patients admitted with stroke typically 
ranges from 2% to 6.5%.12 Of relevance for the pathogen-
esis of brain infarction in CABM, a previous autopsy study 
of patients with pneumococcal meningitis documented 
extensive infarction and thrombosis in such patients and 
the authors hypothesised that infectious cerebral vasculitis 
or inflammation mediated by deposition of immune-com-
plexes may be involved.13 This could potentially explain 
some of the observed associations between seizures, cere-
bral infarction and pneumococcal meningitis observed 
in our study. Further support may be derived by cerebral 
oedema or other intracranial complications being infre-
quent in patients with and without seizures in our study. 
Of note, studies remain inconclusive regarding the role 
of adjunctive dexamethasone in the rare occurrence of 
delayed-onset stroke after bacterial meningitis.14 15
Two other studies reported seizures more often among 
elderly (>65 and 60 years of age, respectively) than in 
younger CABM patients, but multivariable analyses of 
risk factors for seizures were not reported.2 16 Although 
the point estimates in our univariate and multivariate 
analyses consistently suggest age >65 years as a potential 
risk factor for seizures in CABM, the confidence intervals 
Table 6 Multivariate analyses for risk factors of seizures in CABM using patients with no seizures as reference
Risk factor for seizures during CABM Derivation cohort (n=358) Validation cohort (n=379)
Seizures at any time during infection n=62 (17%) n=69 (18%)
Age >65 years 1.40 (0.90 to 2.18) 1.43 (0.90 to 2.29)
Immunocompromise 1.42 (0.92 to 2.19) 1.44 (0.93 to 2.23)
Pneumococcal aetiology 1.69 (1.01 to 2.83) 1.69 (1.10 to 2.59)
Abnormal cranial imaging 2.27 (1.46 to 3.53) 1.68 (1.09 to 2.59)
Antibiotic therapy for meningitis within 2 hours of admission 0.98 (0.63 to 1.54) 0.94 (0.57 to 1.54)
Adjunctive dexamethasone treatment 1.05 (0.68 to 1.63) 0.83 (0.51 to 1.34)
Seizures during admission n=58 (16%) N=46* (12%)
Age >65 years 1.48 (0.93 to 2.35) 1.60 (0.90 to 2.85)
Immunocompromise 1.59 (1.01 to 2.50) 1.30 (0.76 to 2.25)
Pneumococcal aetiology 1.62 (0.96 to 2.73) 1.92 (1.12 to 3.29)
Abnormal cranial imaging 2.23 (1.40 to 3.54) 1.59 (0.92 to 2.77)
Antibiotic therapy for meningitis within 2 hours of admission 0.96 (0.60 to 1.53) -
Adjunctive dexamethasone treatment 1.23 (0.77 to 1.95) -
Data are presented as relative risks with 95% CI.
*The limited number of events in this group restricted the number of variables included in the adjusted model as described under ‘Statistical 
analyses’.
CABM, community-acquired bacterial meningitis.
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indicate too much statistical uncertainty for this to be a 
confirmed risk factor for now.
Similar to our study, other reports have examined 
seizures as a prognostic factor in bacterial meningitis and 
found increased risks of case fatality and unfavour-
able outcome.2 4 16–18 A prognostic model based on 176 
patients with CABM from 1970 through 1995 showed an 
increased risk of in-hospital mortality or neurological 
deficits at discharge in patients with seizures at admis-
sion (OR 4.42, 95% CI 1.56 to 12.48).17 The model was 
adjusted for immune-competence, comorbidity and CSF 
leucocyte count and subsequently validated in a second 
cohort. Another study also observed an increased risk 
of in-hospital mortality in univariate analysis of bacte-
rial meningitis patients with seizures within 24 hours of 
admission (RR 4.0, 95% CI 2.8 to 5.8).4 Likewise, a third 
study found seizures occurring after treatment initiation 
for CABM in elderly patients to be associated with in-hos-
pital mortality (OR 6.8, 95% CI 1.7 to 27).2 The authors 
also state a protective effect of several variables including 
anti-seizure prophylaxis, but neither these results nor the 
statistical models were presented.
Finally, a large study of 352 patients with pneumo-
coccal meningitis found an equal distribution of seizures 
at presentation among those with favourable outcome 
(8%) and unfavourable outcome (6%).19 This suggests 
that some of the observed prognostic effect of seizures on 
mortality and unfavourable outcome in our study could 
be related to seizures after admission or pneumococcal 
aetiology, even though we adjusted for the latter in our 
models.
limitations
Several conditions could result in an underestimation 
of the cumulative incidence of seizures in CABM. These 
include patients admitted comatose without a detailed 
patient history, requests for cranial imaging before lumbar 
puncture with the risk of death before the diagnosis is 
confirmed (by lumbar puncture) or because a contraindi-
cation to lumbar puncture is present, for example, intra-
cranial mass lesion. On the other hand, antibiotics used 
for CABM have been associated with a low absolute risk of 
seizures, which may lead to an increase in the incidence 
of seizures in these patients. However, we consider this 
negligible compared with the effect of severe inflamma-
tion of the meninges, high fever, brain infarctions and 
sepsis.
The categorisation of seizures into those occurring 
before or immediately at admission and those after admis-
sion is arbitrary, and may be influenced by, for example, 
time to diagnosis and disease severity. However, the 
distinction has clinical relevance, as seizures occur-
ring after admission could be a target for prevention. 
Compared with patients without seizures, patients with 
seizures more often had cranial imaging performed in 
our study and were therefore more likely to be diagnosed 
with, for example, brain infarctions. Still, other abnor-
malities on cranial imaging did not differ suggesting 
a true difference in occurrence of clinically relevant 
infarctions between the two patient groups. More-
over, the occurrence of brain infarctions was similar in 
frequency to another study in which the cranial imaging 
was performed equally often among patients with and 
without seizures during CABM.1 A point of consideration 
is that MRI is more sensitive than CT in detecting brain 
infarctions but it was seldom used in our patients. This 
may have led to an underestimation in the incidence of 
intracranial abnormalities.
Other limitations inherent of observational studies also 
apply to our results. Some details concerning, for example, 
number and type of seizures as well as type of cranial 
imaging or distribution of infarctions were not always 
well described in the medical records. Further, reports 
of EEG were unavailable, which may underestimate the 
incidence of subclinical or non-convulsive status among 
patients with impaired consciousness Nonetheless, both 
frequency and seizure characteristics were comparable to 
a previous study with such information available.1 Missing 
values were accounted for by providing exact numbers 
of observations in the tables. Unfortunately, we only had 
sporadic information on intracranial pressures and were 
unable to perform meaningful analysis of associations 
with occurrence of seizures. Finally, the treatment of 
patients was performed by the responsible physician and 
may as such be subject to variation.
Implications
We agree with Zoons et al that a low threshold for anti-
convulsant therapy in patients with seizures in CABM 
is prudent.1 Although the observed mortality with 
seizures in patients with CABM is high, causality cannot 
be inferred by observational studies and the associa-
tions could be due to, for example, pneumococcal aeti-
ology, infarctions or disease severity. Therefore, routine 
anticonvulsive treatment to patients with CABM is not 
advised for now. Non-convulsive status was rare in our 
and other studies, but should be considered in patients 
with unexplained fluctuating consciousness or those 
who do not regain consciousness.1 Prolonged or intensi-
fied anti-inflammatory treatment could be considered in 
future experimental studies if infectious cerebral vascu-
litis is confirmed as an important contributor to infarc-
tions, seizures and fatal outcome in a substantial part of 
patients with pneumococcal meningitis. Our observations 
were confirmed in a separate prospective cohort, and the 
characteristics associated with risk of seizures and adverse 
outcome could, together with findings in other studies, 
help define a patient population eligible for clinical trials 
of prophylactic anti-epileptic drugs in adults with CABM.
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